Retatrutide, an investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors, has shown considerable promise for obesity and type 2 diabetes — but can retatrutide make you dizzy? Clinical trial data suggest dizziness has been reported as an adverse effect, though it is less common than gastrointestinal symptoms such as nausea and vomiting. Several mechanisms may contribute, including reduced caloric intake, blood pressure changes, and hypoglycaemia. As retatrutide is not yet approved by the MHRA, its full safety profile continues to be established through ongoing trials.

Can Retatrutide Cause Dizziness?

Retatrutide can cause dizziness, as reported in Phase 2 trials, though it is less common than gastrointestinal side effects; the full safety profile remains under investigation as Phase 3 data are awaited.

Retatrutide is an investigational triple hormone receptor agonist under clinical development for the treatment of obesity and type 2 diabetes. It acts simultaneously on glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors — a mechanism that distinguishes it from currently approved therapies such as semaglutide (Ozempic®, Wegovy®) or tirzepatide (Mounjaro®). Because retatrutide has not yet received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), its full safety profile is still being established through ongoing clinical trials.^[3][5]

Dizziness has been reported by some participants in retatrutide clinical trials. A randomised, double-blind, placebo-controlled Phase 2 trial published in the New England Journal of Medicine in 2023 recorded dizziness among adverse events, though it was not among the most frequently reported side effects in that study.^[1] Dizziness is also a recognised adverse effect across the broader GLP-1 receptor agonist class, as documented in the UK Summary of Product Characteristics (SmPC) for licensed medicines such as tirzepatide (Mounjaro®) and semaglutide (Ozempic®/Wegovy®).

It is important to note that dizziness can arise through several different mechanisms, and not all episodes are directly attributable to the drug itself. Factors such as reduced caloric intake, changes in blood pressure, and alterations in blood glucose levels — all of which can occur during treatment — may independently contribute to feelings of lightheadedness or unsteadiness. The evidence base for retatrutide remains limited until Phase 3 data are available, and the frequency and severity of dizziness may be refined as larger studies report their findings.

Understanding why dizziness may occur, how frequently it has been reported, and how to manage it safely are all important considerations for anyone involved in or considering participation in a clinical trial involving this agent.

Why Dizziness May Occur With Retatrutide

Dizziness with retatrutide is multifactorial, arising from appetite-related dehydration, blood pressure reductions (including orthostatic hypotension), hypoglycaemia risk with concurrent glucose-lowering drugs, and nausea-induced fluid loss.

The mechanisms by which retatrutide may cause dizziness are multifactorial, and understanding them helps contextualise the symptom within the broader pharmacological profile of the drug.

Reduced caloric intake and dehydration: Retatrutide suppresses appetite, which may in some individuals lead to a reduction in food and fluid intake. This can contribute to mild dehydration or electrolyte imbalance — both well-established causes of dizziness and postural lightheadedness. The NHS advises aiming for around 6–8 drinks per day (more in hot weather or when unwell), unless a clinician has advised otherwise.

Blood pressure changes: GLP-1 receptor agonists are associated with modest reductions in blood pressure, an effect that may be partly related to weight loss.^[7] The precise contribution of retatrutide's additional receptor activity to blood pressure changes is still being characterised in clinical studies. A drop in blood pressure — particularly upon standing (orthostatic hypotension) — can cause transient dizziness, especially in the early weeks of treatment or following dose escalation. Patients taking antihypertensive medicines or diuretics should discuss this with their clinician, as dose adjustments may be needed.

Hypoglycaemia: Retatrutide's insulin-stimulating effects are glucose-dependent, which reduces — but does not eliminate — the risk of low blood glucose.^[2][1] The risk of hypoglycaemia is meaningfully increased when retatrutide is used alongside insulin or sulfonylureas, consistent with the established class precedent for GLP-1 receptor agonists (as documented in the SmPCs for tirzepatide and semaglutide).^[8][9] Symptoms of hypoglycaemia include dizziness, shakiness, and confusion, and dose adjustments to concurrent glucose-lowering therapies may be required.

Gastrointestinal effects: Nausea and vomiting, which are among the most commonly reported side effects of retatrutide, can themselves contribute to dizziness through fluid loss and general malaise.

These mechanisms are not mutually exclusive, and in practice, dizziness during retatrutide treatment may reflect a combination of contributing factors rather than a single cause.

How Common Is Dizziness in Clinical Trials?

Dizziness was reported in the 2023 Phase 2 trial but was less frequent than gastrointestinal adverse effects; it appeared mild to moderate in severity and may be more common at higher doses.

Retatrutide has been evaluated in a Phase 2 clinical trial — a randomised, double-blind, placebo-controlled study published in the New England Journal of Medicine in 2023. This trial assessed multiple doses of retatrutide in adults with obesity over 24 weeks and reported substantial weight loss across all active treatment groups.^[1] Dizziness was recorded among adverse events during the study, though it was not identified as one of the most frequently reported side effects.

The most commonly reported adverse effects in the trial were gastrointestinal in nature — including nausea, diarrhoea, vomiting, and constipation — which is consistent with the broader GLP-1 receptor agonist class.^[1][5] Dizziness was reported at a lower frequency than these gastrointestinal symptoms, and in most cases was described as mild to moderate in severity. Available data suggest the incidence may be somewhat higher at greater doses and during periods of dose escalation, though precise figures by dose group and comparison with placebo rates should be sought from the published trial data directly.

It is important to note that Phase 2 trials are not powered to detect all adverse effects with the same precision as larger Phase 3 studies. As retatrutide progresses through further clinical development, a more comprehensive and statistically robust picture of the frequency and severity of dizziness — and how it compares to placebo — will emerge. At present, the available data suggest that whilst dizziness is a recognised adverse effect, it does not appear to be among the most prevalent or severe complications associated with the drug. Patients enrolled in trials should nonetheless report any episodes of dizziness to their trial team promptly.

Managing Dizziness Whilst Taking Retatrutide

Practical management includes staying well hydrated, rising slowly from sitting or lying positions, eating small regular meals, avoiding alcohol and excessive heat, and monitoring blood glucose if taking concurrent antidiabetic medicines.

For individuals experiencing dizziness during retatrutide treatment — whether within a clinical trial or, in future, as part of licensed clinical use — several practical strategies may help reduce the frequency and severity of symptoms.

Stay well hydrated: Because appetite suppression may inadvertently reduce fluid intake in some people, making a conscious effort to drink regularly throughout the day is important. The NHS recommends aiming for around 6–8 drinks per day (such as water, lower-fat milk, or sugar-free drinks), and more during hot weather or illness, unless your clinician has advised you to restrict fluids.^[11]

Do not drive or operate machinery if you feel dizzy or faint: Dizziness can impair your ability to react safely. Avoid these activities until symptoms have fully resolved.

Rise slowly from sitting or lying positions: If dizziness is related to orthostatic hypotension, taking care when changing posture — pausing briefly before standing fully upright — can help the body adjust blood pressure more gradually and reduce lightheadedness. If you are taking antihypertensive medicines or diuretics and experience persistent symptoms on standing, speak to your clinician, as a medication review may be appropriate.

Eat regular, small meals: Maintaining a consistent pattern of small, nutritious meals can help stabilise blood glucose levels and reduce the risk of hypoglycaemia-related dizziness, even when overall appetite is reduced.

Avoid known triggers: Alcohol, excessive heat, and prolonged standing can all exacerbate dizziness, particularly in the context of blood pressure changes. Minimising these where possible during the early stages of treatment or following dose increases is advisable.

Monitor blood glucose if applicable: Individuals with type 2 diabetes who are also taking insulin or sulfonylureas should monitor their blood glucose levels as directed by their clinical team, as dose adjustments to concurrent therapies may be necessary to reduce hypoglycaemia risk.

Dose escalation schedules for retatrutide are typically gradual, which helps the body adapt to the drug's effects over time. Many individuals find that dizziness, if present, improves as treatment continues and the body acclimatises to the medication.

When to Seek Medical Advice

Seek urgent medical advice if dizziness is persistent, worsening, or accompanied by fainting, chest pain, or neurological symptoms such as facial drooping or limb weakness, which require immediate emergency assessment.

Whilst mild, transient dizziness is generally not a cause for alarm, there are certain circumstances in which prompt medical attention is warranted. Knowing when to contact a GP, trial clinician, NHS 111, or the emergency services is an important aspect of patient safety.

Contact your GP or trial team if:

• Dizziness is persistent, worsening, or significantly affecting your daily activities

• You experience dizziness accompanied by nausea, vomiting, or an inability to maintain adequate fluid intake

• You notice dizziness occurring consistently when standing up, which may indicate orthostatic hypotension requiring assessment

• You are also taking antidiabetic medications and suspect your blood glucose may be low

If you are unable to reach your GP or trial team and need urgent advice, call NHS 111 (available 24 hours a day). They can advise on next steps and direct you to the appropriate service.

Call 999 or go to your nearest emergency department immediately if:

• You experience sudden, severe dizziness with loss of balance, difficulty speaking, facial drooping, or weakness in the limbs — these may be signs of a stroke and require immediate assessment

• You faint or lose consciousness

• You experience chest pain or severe shortness of breath alongside dizziness

For those participating in a clinical trial, all adverse events — including dizziness — should be reported to the trial team in accordance with the study protocol, regardless of perceived severity. This is essential for the accurate characterisation of the drug's safety profile and for the protection of all trial participants. Do not discontinue retatrutide without first consulting your supervising clinician, as abrupt cessation may have implications for the trial and your ongoing care.

For licensed medicines, suspected side effects can also be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Trial participants should follow their study protocol for adverse event reporting.

Current Availability and Guidance in the UK

Retatrutide is not approved for clinical use in the UK and cannot be legally prescribed outside a regulated clinical trial; patients should discuss currently NICE-recommended options such as semaglutide or tirzepatide with their GP.

As of the time of writing, retatrutide is not approved for clinical use in the United Kingdom. It has not received a marketing authorisation from the MHRA, nor has it been evaluated or recommended by the National Institute for Health and Care Excellence (NICE). It therefore cannot be legally prescribed or dispensed outside of a regulated clinical trial setting.

Retatrutide is being developed by Eli Lilly and Company.^[1][3] Following the Phase 2 results published in 2023, a Phase 3 clinical programme has been announced; patients interested in the current development status or trial availability should consult the manufacturer's communications or the ClinicalTrials.^[3][6]gov registry for up-to-date information, as the programme is ongoing and details may change. Larger Phase 3 studies will provide more robust data on efficacy, long-term safety, and tolerability — including a more detailed understanding of adverse effects such as dizziness — across broader and more diverse patient populations. Should Phase 3 results prove favourable, the manufacturer would be expected to submit a regulatory dossier to the MHRA and EMA for marketing authorisation review.

In the meantime, patients in the UK who are interested in weight management or type 2 diabetes treatment should speak with their GP about currently approved and NICE-recommended options. These include licensed GLP-1 receptor agonists such as semaglutide (Wegovy® for weight management; Ozempic® for type 2 diabetes) and tirzepatide (Mounjaro®), both of which have established safety profiles and are subject to NICE technology appraisal guidance. Patients wishing to explore legitimate clinical trial opportunities can visit the NIHR's Be Part of Research service (bepartofresearch.nihr.ac.uk).

It is strongly advised that patients avoid purchasing any substance marketed as retatrutide from unregulated online sources. Such products are not subject to quality or safety oversight, carry significant health risks, and are not the same as the investigational compound used in clinical trials. Always seek guidance from a registered healthcare professional before starting any new treatment for weight management or metabolic conditions.

Frequently Asked Questions